Transfermoral transcatheter aortic valve implantation using self-expanding Allegra bioprosthesis: One-year single-center outcomes by Milan, Joanna et al.
Address for correspondence: Dr. Mirosław Gozdek, Department of Cardiology and Internal Medicine, Nicolaus Copernicus  
University, Collegium Medicum in Bydgoszcz, ul. M. Skłodowskiej-Curie 9, 85–094 Bydgoszcz, Poland, e-mail: gozdekm@wp.pl
Received: 29.04.2020 Accepted: 25.01.2021 Early publication date: 17.08.2021
*Both authors equally contributed to the study.
This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download 
articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
Transfermoral transcatheter aortic valve  
implantation using self-expanding Allegra  
bioprosthesis: One-year single-center outcomes
Joanna Milan1*, Mirosław Gozdek2, 3, 4*, Radosław Targoński8,  
Mariusz Kowalewski4, 5, 6, Aleksandra Stańska8, Marcin Fijałkowski1,  
Romuald Lango7, Miłosz Jaguszewski1, Dariusz Jagielak8
11st Department of Cardiology, Medical University of Gdansk, Poland; 2Department of Cardiology and  
Internal Medicine, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Poland;  
3Department of Cardiac Surgery, Medinet Heart Center Ltd., Wroclaw, Poland; 4Thoracic Research Center, 
Collegium Medicum, Nicolaus Copernicus University, Innovative Medical Forum, Bydgoszcz, Poland;  
5Clinical Department of Cardiac Surgery, Central Clinical Hospital of the Ministry of Interior and  
Administration, Center of Postgraduate Medical Education, Warsaw, Poland; 6Department of Cardio- 
-Thoracic Surgery, Heart and Vascular Center, Maastricht University Medical Center, Maastricht,  
The Netherlands; 7Department of Cardiac Anesthesiology, Medical University of Gdansk, Poland 
8Department of Cardiac and Vascular Surgery, Medical University of Gdansk, Poland
Abstract 
Background: The NAUTILUS study aimed to evaluate the safety and performance of the ALLegrA 
bioprosthesis in high-risk recipients undergoing transcatheter aortic valve implantation and previously 
reported 30-day outcomes. In the current investigation 1-year results of the trial are presented.
Methods: Twenty-seven recipients with severe, symptomatic aortic valve stenosis at high surgical risk, 
who underwent treatment using the next-generation self-expanding Allegra via transfemoral approach 
were prospectively enrolled. Clinical endpoints assessed were: mortality, stroke, permanent pacemaker 
implantation, New York Heart Association class and re-hospitalizations. Prosthetic valve performance 
evaluation comprised of: mean gradient, effective orifice area and paravalvular leak.
Results: Patients were elderly (82.8 ± 4.2 years) and predominantly female (n = 19, 70.4%). All of 
them were deemed to be at high surgical risk with a mean logistic euroSCOre of 12.5 ± 6.7. The 
bioprosthesis was successfully implanted in 92.6% of the cases (n = 25). At 1-year, all-cause mortality 
was 12.0% (n = 3) and stroke was 4.0% (n = 1). Three (12%) of patients developed complete atrioven-
tricular block and received permanent pacemakers. 84% of patients were in New York Heart Associa-
tion class II or lower. Need for subsequent hospitalization arose in 48% patients. The echocardiographic 
assessment confirmed an acceptable hemodynamic profile of the Allegra with low mean transprosthetic 
gradient (9.5 ± 3.4 mmHg), absence of severe paravalvular leak and a 20%-presence of moderate 
paravalvular leak. 
Conclusions: The current follow-up observation study shows that the Allegra was associated with  
a satisfactory safety profile and hemodynamic performance at 1-year after implantation. (Cardiol J 
2021; 28, 6: XXX–XXX)
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Since its introduction by Cribier in 2007 [1], 
transcatheter aortic valve implantation (TAVI) has 
complemented surgical aortic valve replacement 
(SAVR) in patients with severe symptomatic aor-
tic valve stenosis (AVS). This minimally invasive 
technique at first presented an opportunity to treat 
inoperable individuals and ultimately has become 
common and standard in higher-risk patients. The 
Allegra TAVI System (NVT, Germany) bioprosthe-
sis is a next-generation, self-expanding device, 
dedicated for TAVI and is designed to overcome the 
limitations of first-generation systems including 
firstly, paravalvular leak (PVL) and the necessity 
for permanent pacemaker implantation (PPI). The 
first-in-human clinical trial with implantations of the 
Allegra took place in 2013 by Wenaweser et al. [2]. 
To date, several conducted studies showed encour-
aging short-term outcomes in treating patients 
with severe aortic native valve stenosis using New 
Valve Technology (NVT) devices [2–4], but longer-
term results are lacking. Herein, are presented 
1-year single-center results with the Allegra.
Methods
NAUTILUS (NVT trAnsfemoral mUlticentric 
aorTIc valve pivotaL stUdy for Safety and effective-
ness — DRKS00006042) is a single-arm clinical 
study conducted at 8 centers in 3 countries (Swit-
zerland, Poland, and Brazil), designed to assess 
the safety and performance of the Allegra and, as 
it has been described in detail before, along with 
implantation protocol [3].
In brief, we previously reported on a single-
-center’s early outcomes with the Allegra (Suppl. 
Fig. 1) implanted in 26 patients accepted by the 
Heart Team to undergo transfemoral TAVI. All 
patients suffered from severe, symptomatic AVS 
and met the NAUTILUS eligibility criteria. The 
main inclusion criteria were: 1) age ≥ 75 years; 
2) symptomatic (New York Heart Association 
[NYHA] class II or greater), severe degenerative 
native aortic stenosis (mean transvalvular pressure 
gradient > 40 mmHg and/or aortic jet velocity 
> 4.0 m/s and/or aortic valve area of < 1.0 cm2 [or 
aortic valve area index ≤ 0.6 cm2/m2]); 3) high risk 
for surgical aortic valve replacement with a logistic 
EuroSCORE ≥ 20% or documented agreement of 
the Heart Team that the patient is at high risk for 
surgery due to frailty and/or coexisting comorbidi-
ties. Amongst others, the protocol defined exclu-
sion criteria comprised: 1) unicuspid or bicuspid 
valve disease; 2) non-calcified aortic valve disease; 
3) mixed valve disease with predominant aortic 
regurgitation greater than 3+ or with associated 
severe (greater than 3+) mitral regurgitation; 
4) aortic annulus size < 19 mm or > 29 mm; 
5) type of femoral access, or any other anatomical 
conditions that prevented the safe placement of an 
18 French introducer sheath and manipulation of 
the TAVI system (e.g. severe femoral-iliac obstruc-
tive calcification or tortuosity).
Patients were followed-up for 1 year. Written 
informed consent was obtained from each partici-
pant. The study was approved by the local ethics 
committee.
The data for the clinical trial was collected 
prospectively in an outpatient setting by using 
a dedicated electronic case report form. End points 
in the analysis included all-cause mortality, stroke, 
PPI, re-hospitalizations, re-hospitalizations for 
cardiovascular causes. Most patients underwent 
transthoracic echocardiography. Hemodynamic 
prosthesis performance assessment included mean 
pressure gradient, effective orifice area, presence 
and grade of PVL. Continuous variables are pre-
sented as mean ± standard deviation. Categorical 
variables are given as frequencies and percentages 
and were compared by the Fisher exact test. A two-
-sided p-value < 0.05 was considered statistically 
significant if applicable. Statistical analysis was 
performed using STATISTICA 12.0 PL (StatSoft).
Results
Baseline characteristics of the study group 
is listed in Table 1. The patients’ population was 
elderly with a mean age of 82.8 ± 4.2 years, 70.4% 
were female and the mean logistic EuroSCORE 
was 12.5 ± 6.7. Twenty-six patients were im-
planted with the Allegra valve. The procedure 
was successfully completed in 25 (92.6%) of them. 
One individual required open-heart aortic valve 
replacement due to dislocation of the prosthesis 
into the left ventricle. The patient selection pro-
cess and reasons for exclusion of proportions of 
them are described in Supplementary Figure 2. 
Mean follow-up was 12.4 ± 2.3 months. Three 
(12%) patients died within the study period. Stroke 
was recorded in 1 (4%) individual. Three (12%) 
recipients developed complete atrioventricular 
block and received permanent pacemakers. Last-
ing improvement in patients’ functional class was 
noted (Fig. 1). Most individuals (84%) were in 
II or less NYHA class. Twelve patients (48%) 
needed rehospitalization during follow-up period. 
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Seven individuals (58%) had cardiovascular rea-
son for subsequent hospital stay, but none was 
prosthesis-related. The cardiovscular causes were: 
chronic heart failure exacerbation in two patients, 
hypertension in another two, complete atrio-
-ventricular block, supraventricular arrhythmia 
and stroke (Table 2).
The echocardiographic assessment on follow-
up showed excellent hemodynamic performance. 
The study group had a low mean transprosthetic 
gradient (9.5 ± 3.4 mmHg) and suitable effective 
aortic orifice area (1.48 ± 0.39 cm2). The major-
Table 1. Baseline characteristics and parameters 
(n = 27). 
Age [years] 82.8 ± 4.2
Male 8 (29.6%)
Female 19 (70.4%)




Coronary artery stenosis > 50% 2 (7.4%)
Previous myocardial infarction 7 (25.9%)
Previous coronary surgery 4 (14.8%)
Previous coronary angioplasty 12 (44.4%)
Previous stroke or TIA 1 (3.7%)






Conduction disorders (LBBB, RBBB, AVB) 2 (7.4%)
Pre-existing permanent pacemaker 3 (11.1%)
Aortic valve insufficiency (≥ mild) 11 (40.7%)
Mitral valve insufficiency (≥ mild) 18 (66.7%)
AVB — atrioventricular block; COPD — chronic obstructive pulmo-
nary disease; LBBB — left bundle branch block; NYHA — New York 
Heart Association functional class; RBBB — right bundle branch 
block; TIA — transient ischemic attack
Table 2. Clinical outcomes and adverse events at 
1-year follow-up (n = 25). 
All-cause mortality 3 (12%)
Cardiovascular mortality 3 (12%)
Myocardial infarction 0 (0%)
Stroke and/or TIA 1 (4%)
Minor bleeding 1 (4%)
Renal failure 1 (4%)
Vascular complication 0 (0%)
Sepsis 2 (8%)
Endocarditis 0 (0%)
Permanent pacemaker implantation 3 (12%)











CHF exacerbation 2 (8%)
Hypertension 2 (8%)
Complete AVB 1 (4%)







Infection of the wound 1 (4%)
AVB — atrioventricular block; CHF— chronic heart failure; NYHA — 
New York Heart Association; TIA — transient ischemic attack
Figure 1. New York Heart Association (NYHA) functional 
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ity of patients (80.0%) had only mild or less PVL, 
while 20% moderate and 0% severe were noted. 
Figures 2 and 3 present changes of prosthetic aor-
tic valve area, mean transprosthetic gradient and 
paraprosthetic leak in the study population during 
observation.
Discussion
The current study is the single-center experi-
ence of the next-generation, self-expanding, tran-
scatheter and transfemoral Allegra bioprosthesis 
and, according to available research, is the only one 
that presents outcomes in long-term follow-up. The 
study revealed a favorable valve hemodynamic pro-
file with low transvalvular gradient and no severe 
PVLs. Three deaths, one cerebrovascular incident, 
as well as a low rate of permanent pacemaker im-
plantation (12%) were recorded during the follow-
up period. Twelve patients needed subsequent 
hospitalization. 
The study revealed no severe PVL. However, 
20% moderate and 50% mild PVLs occurred in the 
Allegra recipients at 1-year. Only two transcatheter 
devices were commercially available within the 
initial few years after the first procedure: the self-
-expandable CoreValve (Medtronic, USA) and the 
balloon-expandable Sapien (Edwards Lifesciences 
Corporation, USA). Early-generation transcath-
eter valves, despite providing good clinical out-
comes, were not free from shortcomings such as 
a high rate of conduction abnormalities demanding 
PPI, vascular complications or more importantly 
a higher incidence of PVL, which was consequently 
associated with increased late mortality and higher 
rate of other adverse clinical incidents as com-
pared to SAVR [5, 6]. Several potential causes 
of PVL such as severe native valve calcification, 
suboptimal artificial valve sizing, positioning and 
deployment, and prosthesis construction itself are 
universally reported across available literature. To 
minimize these shortcomings technological innova-
tions, with respect to both delivery systems and 
the valve itself were developed in next-generations 
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devices, including the Allegra. The outer part of 
the valve’s stent is covered by 12-mm bovine peri-
cardial sealing skirt reducing the risk of significant 
paravalvular leak. The NVT system is able to re-
position and retrieve the prosthesis in case of mal-
position or a suboptimal result. The Allegra valve 
has features allowing for very precise positioning. 
The presence of radiopaque markers in the delivery 
system as well as at the transition between the 
annular skirt and the bottom of the leaflets mark-
edly facilitates the procedure, by enabling direct 
and clear visualization of the optimal implantation 
height and the limits of the sealing skirt. 
A different grade of PVL was a common com-
plication of early-generation TAVI devices and was 
associated with worse survival [7, 8]. Moreover, 
long-term follow-up data suggested that even mild 
paravalvular regurgitation was associated with in-
creased late mortality with the balloon-expandable 
Sapien [5] and with the self-expandable CoreValve, 
early-generation valves [9, 10]. Moderate to severe 
PVL occurred in 7.8% of CoreVale implantations 
and mild paravalvular aortic regurgitation was 
reached in one-third of cases in 1-year observation 
by Adams et al. [11] as well as 4.2% and 29.1%, 
respectively, in a study by Popma et al. [12]. The 
next iteration of the Medtronic valve, the Evolut R, 
was associated with 1.2% of moderate PVL at 
1-year observation by Manoharan et al. [13]. 
Newer-generation, self-expanded the Acurate neo 
(Boston Scientific) in study by Mauri et al. [14] 
presented no severe, 3.9% moderate and 47.1% 
mild PVL at 1-year follow-up. 
Popma et al. [12] revealed that the frequency 
of moderate or severe PVL was lower 12 months 
after CoreValve TAVI (4.2%) than at discharge 
(10.7%). Oh reported 83% of CoreValve recipients 
have at least one degree of regression in PVL dur-
ing 1-year follow-up [15]. Structural properties of 
nitinol-based frame are probably the explanation 
of this phenomenon. Progressive expansion of 
the self-expanding valve improved paravalvular 
sealing. Results of the current study confirm the 
trend of decreasing PVL frequency over time, but 
only concerning mild PVL.
The overall risk of the early permanent atrio-
ventricular conduction disturbances and need 
for PPI following TAVI procedures varies, but 
remains around 17% [16]. In comparison to the 
balloon-expandable valves, the self-expandable 
TAVI prostheses have a slightly higher rate of 
postprocedural atrio-ventricular conduction block 
requiring pacemaker implantation (28%) [17, 18]. 
In our study only 12% of patients required PPI in 
longer follow-up compared to 8% in 30-day ob-
servation. In comparison to other self-expandable 
older and newer-generation prostheses. This is 
a very promising result. Adams et al. [11] and 
Popma et al. [12] reported 22.3% and 26.2% need 
of PPI for CoreValve, Manoharan [13] 19.7% for 
Evolut R recipients in 1-year. Such a good result 
may be related to a high valve implantation facili-
tated by refined deployment technology and the 
Allegra design. However, it seems atrio-ventricular 
conduction disturbances revealed a month after the 
procedure are rather not related to TAVI.
The effect of PPI on long-term outcomes after 
TAVI remains inconclusive [19, 20]. Post-TAVI 
PPI was reported as an independent predictor of 
1-year mortality [19] and was also associated with 
a longer duration of hospitalization and higher rates 
of re-hospitalization at 1 year [21]. In contrast, an 
analysis including more than 1500 TAVI procedures 
the need for PPI did not increase overall mortality, 
cardiovascular death or re-hospitalization for heart 
failure within 2 years [22]. Moreover, Engborg et 
al. [23] reported even higher survival rate in TAVI-
patients with a permanent pacemaker implanted.
The present study revealed 12% of mortality. 
In the article by Adams et al. [11] as well as by 
Popma et al. [12] concerning 1-year results after 
TAVI utilizing the early-generation self-expandable 
CoreValve, mortality was estimated at 13.9% and 
24.3%, respectively. With regards to the next-
generation devices, Manoharan et al. [13] reported 
8.9% of mortality among Evolut R self-expandable 
prosthetic valve recipients at high or greater surgi-
cal risk. In turn, Barth et al. [24] and Mauri et al. 
[14] in studies with the self-expandable Acurate 
neo implanted in the high surgical risk patients 
revealed 16.9% and 8.3% mortality ratios in 1-year 
observations, respectively.
In the current investigation, despite a disturb-
ingly high rate of moderate and mild PVL, mortality 
remains low, lower than recorded in early genera-
tion self-expandable valves and is comparable with 
the other next-generation devices.  
These results suggest that the Allegra has 
an acceptable efficacy profile in treating elderly 
patients with severe symptomatic AVS, although 
further studies are warranted to fully elucidate 
this issue.
The present study has some important limita-
tions. It is an observational, single-arm study of 
a small sample size which, per se, precludes any 
in-depth comparison against a control group or 
detailed analyses related to uncommonly occur-
ring events.
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Conclusions
This prospective study shows a good safety 
and performance profile of the Allegra. The valve 
has a satisfactory hemodynamic performance and 
encouraging clinical results with a low rate of 
pacemaker implantations. 
Conflict of interest: None declared
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